Table 5. Sensitivity of results to level of CrAg screening and proportion of patients with meningitis treated.

Results	Strategy	Cost of Screening	Cost of preemptive treatment	Cost of treatment for meningitis	Total Cost	Deaths	Note
SA.a	No screening or treatment for CM	0	0	0	0	10075	Do nothing
SA.b	No screening, 50% hospitalized (CM treatment with amphotericin + fluconazole)	0	0	$2,528,052	$2,528,052	6448	Dominated by SA.d if slightly larger budget possible
SA.c	No screening, 80% hospitalized. CM treatment with amphotericin + fluconazole	0	0	$4,044,882	$4,044,882	4272	Dominated by SA.d and base case
SA.d	CrAg screening, 50% hospitalized (CM treatment with amphotericin + fluconazole)	$436,314	$295,431	$2,078,920	$2,810,665	3538	CrAg screening with 50% of patients being hospitalized has essentially the same total costs as the same amount of hospitalization without screening (SA.b), but an additional 2,910 lives are saved annually.
Base case results	CrAg screening, 80% hospitalized (CM treatment with amphotericin + fluconazole)	$436,314	$295,431	$2,624,979	$3,356,724	2755